François Dauphin Selected Research

(endo- N- 8- methyl- 8- azabicyclo(3.2.1)oct- 3- yl)- 2,3- dihydro- 3- ethyl- 2- oxo- 1H- benzimidazol- 1- carboxamide

6/2003

BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

François Dauphin Research Topics

Disease

3	Alzheimer Disease (Alzheimer's Disease) 08/2017 - 11/2004
2	Cognitive Dysfunction 01/2014 - 06/2003
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/2007 - 06/2003
1	Memory Disorders (Memory Loss) 08/2017
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2012
1	Infarction (Infarctions) 11/2007
1	Stroke (Strokes) 11/2007
1	Brain Ischemia (Cerebral Ischemia) 06/2003

Drug/Important Bio-Agent (IBA)

3	Cholinergic Agents (Cholinergics)IBA 01/2014 - 11/2004
2	5-HT4 Serotonin ReceptorsIBA 08/2017 - 06/2003
2	Scopolamine (Hyoscine)FDA Link 08/2017 - 07/2012
2	RS 67333IBA 08/2017 - 06/2003
2	Opioid Receptors (Opioid Receptor)IBA 11/2007 - 06/2003
2	kappa Opioid Receptors (kappa Opioid Receptor)IBA 11/2007 - 06/2003
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 08/2017
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 08/2017
1	Galantamine (Galanthamine)FDA LinkGeneric 08/2017
1	Pharmaceutical PreparationsIBA 01/2017
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 01/2017
1	LigandsIBA 04/2015
1	AcetylcholinesteraseIBA 04/2015
1	donecoprideIBA 04/2015
1	serotonin 6 receptorIBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 11/2007
1	GalaninIBA 11/2004
1	GR 113808IBA 06/2003
1	indoleIBA 06/2003
1	(endo- N- 8- methyl- 8- azabicyclo(3.2.1)oct- 3- yl)- 2,3- dihydro- 3- ethyl- 2- oxo- 1H- benzimidazol- 1- carboxamideIBA 06/2003

Therapy/Procedure

1	Therapeutics 08/2017